You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
GYKI 52466 dihydrochloride
Biological Activity for GYKI 52466 dihydrochloride
GYKI 52466 dihydrochloride is a selective noncompetitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >50 μM for AMPA-, kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant. Has anti-proliferative effects in transformed cells.
Compound Libraries for GYKI 52466 dihydrochloride
Technical Data for GYKI 52466 dihydrochloride
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for GYKI 52466 dihydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for GYKI 52466 dihydrochloride
The following data is based on the product molecular weight 366.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||5.46 mL||27.3 mL||54.61 mL|
|2.5 mM||1.09 mL||5.46 mL||10.92 mL|
|5 mM||0.55 mL||2.73 mL||5.46 mL|
|25 mM||0.11 mL||0.55 mL||1.09 mL|
Product Datasheets for GYKI 52466 dihydrochloride
References for GYKI 52466 dihydrochloride
References are publications that support the biological activity of the product.
Donevan and Rogawsk (1993) GYKI 52466, a 2,3-benzodiazepine, is a highly selective, non-competitive antagonist of AMPA/kainate receptor responses. Neuron 10 51 PMID: 7678966
Paternain et al (1995) Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 14 185 PMID: 7826635
Rzeski et al (2001) Glutamate antagonists limit tumor growth. Proc.Natl.Acad.Sci.USA 98 6372 PMID: 11331750
Szabados et al (2001) Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res.Bull. 55 387 PMID: 11489346
Tarnawa et al (1989) Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur.J.Pharmacol. 167 193 PMID: 2574112
If you know of a relevant reference for GYKI 52466 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: GYKI 52466 dihydrochloride, GYKI 52466 dihydrochloride supplier, Selective, non-competitive, AMPA, antagonists, Glutamate, Receptors, iGlur, Ionotropic, GYKI52466, dihydrochloride, 102771-26-6, 1454, Tocris Bioscience
18 Citations for GYKI 52466 dihydrochloride
Citations are publications that use Tocris products. Selected citations for GYKI 52466 dihydrochloride include:
Kopach et al (2011) Inflammation alters trafficking of extrasynaptic AMPA receptors in tonically firing lamina II neurons of the rat spinal dorsal horn. Pain 152 912 PMID: 21282008
Li et al (2016) 3'-Deoxyadenosine (Cordycepin) Produces a Rapid and Robust Antidepressant Effect via Enhancing Prefrontal AMPA Receptor Signaling Pathway. Int J Neuropsychopharmacol 19 PMID: 26443809
Fernandes et al (2014) In vitro ischemia triggers a transcriptional response to down-regulate synaptic proteins in hippocampal neurons. PLoS One 9 e99958 PMID: 24960035
Bao et al (2016) Lentinan produces a robust antidepressant-like effect via enhancing the prefrontal Dectin-1/AMPA receptor signaling pathway Behavioural Brain Research 317 263 PMID: 27693847
Park et al (2009) Role of spinal cord alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in complete Freund's adjuvant-induced inflammatory pain. Mol Pain 4 67 PMID: 19116032
Santos et al (2009) Transmission efficacy and plasticity in glutamatergic synapses formed by excitatory interneurons of the substantia gelatinosa in the rat spinal cord. PLoS One 4 e8047 PMID: 19956641
Fritsch et al (2009) Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis. Neuroscience 163 415 PMID: 19540312
Lebrun-Julien et al (2009) Excitotoxic death of retinal neurons in vivo occurs via a non-cell-autonomous mechanism. J Neurosci 29 5536 PMID: 19403821
Huang et al (2004) Astrocyte glutamate transporters regulate metabotropic glutamate receptor-mediated excitation of hippocampal interneurons. J Neurosci 24 4551 PMID: 15140926
Bao et al (2016) The Prefrontal Dectin-1/AMPA Receptor Signaling Pathway Mediates The Robust and Prolonged Antidepressant Effect of Proteo-β-Glucan from Maitake. Sci Rep 6 28395 PMID: 27329257
Farley et al (2010) Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J Neuropsychopharmacol 13 1207 PMID: 20059803
Gerstner et al (2005) Glutaric acid and its metabolites cause apoptosis in immature oligodendrocytes: a novel mechanism of white matter degeneration in glutaryl-CoA dehydrogenase deficiency. Pediatr Res 57 771 PMID: 15774829
Lobb et al (2010) A dynamic role for GABA receptors on the firing pattern of midbrain DArgic neurons. J Neurophysiol 104 403 PMID: 20445035
Vielma et al (2014) Nitric oxide modulates the temporal properties of the glutamate response in type 4 OFF bipolar cells. PLoS One 9 e114330 PMID: 25463389
Du et al (2008) The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci 28 68 PMID: 18171924
Avshalumov et al (2008) AMPA receptor-dependent H2O2 generation in striatal medium spiny neurons but not DA axons: one source of a retrograde signal that can inhibit DA release. J Neurophysiol 100 1590 PMID: 18632893
Bretin et al (2017) Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors. PLoS One 12 e0184429 PMID: 28886144
Lin et al (2008) Integrin regulation of cytoplasmic calcium in excitatory neurons depends upon glutamate receptors and release from intracellular stores. J Pharmacol Exp Ther 37 770 PMID: 18289871
Do you know of a great paper that uses GYKI 52466 dihydrochloride from Tocris? Please let us know.
Reviews for GYKI 52466 dihydrochloride
Average Rating: 5 (Based on 1 Review.)
Have you used GYKI 52466 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Preincubated 40 micromolar of GYKI 52466 for 10 minutes. The image shows the peak fluorescence intensity of fura2-am up on AMPA stimulation. GYKI 52466 efficiently inhibits AMPA receptor-mediated calcium influx.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.